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least once. The total number of patients participating in the study was 85. Of these, 38 were City of Asheville employees who enrolled in March 1997 (sub-group 1) and 47 were MSJ employees who enrolled in March 1999 (subgroup 2). Overall, 43% of eligible patients enrolled in the programme. It was reported that the study had insufficient power to accept the null hypothesis of no difference in results. The authors were aware that patients who chose to participate in the programme might have differed in some important way from those who did not participate, and that this could pose a threat to external validity (selection bias).
Study design
The analysis was part of a larger study, the purpose of which was to assess the short-and long-term clinical, economic and humanistic outcomes of PCS, and possible factors that had an impact on these outcomes. Further details were reported elsewhere (see Other Publications of Related Interest). The basis of the analysis was a within-group comparison study ("before-after" study). The authors initially compared the two sub-groups to determine their comparability. The two sub-groups, which comprised employees of two different employers, had both received the intervention under assessment but on different dates. When no major differences were found in demographic factors and patient outcomes, the two sub-groups were combined for all subsequent analyses based on "before-after" comparisons. In addition, the follow-up results of sub-group 1 were compared with the pre-intervention results of subgroup 2, which, in this case, served as a control group (cohort analysis). The study was conducted in one centre with 12 pharmacies participating. The duration of the pre-intervention period was 12 months. The duration of follow-up was 9 months for sub-group 1 and 7 months for sub-group 2. No loss to follow-up was reported.
Analysis of effectiveness
It was stated that basis of the analysis was intention to treat, therefore selection bias due to drop-outs was avoided. The health outcomes measured included A1c, home blood glucose and lipid levels, a health-related quality of life score, and the patients' satisfaction with pharmacy services. Health-related quality of life was assessed using the Medical Outcomes Study 12-Item Short Form (SF-12), while patient satisfaction with pharmacy services was measured using the Larson and MacKeigan instrument. A preliminary analysis showed the two sub-groups to be comparable for baseline and follow-up outcomes. Therefore, they were combined for all subsequent analyses. In a follow-up analysis, the authors reported that they further controlled for covariates in multivariate models of outcomes, and most covariates were found not to be significant predictors (for further details see Other Publications of Related Interest).
Effectiveness results
The proportion of patients with A1c values in the optimal range (less than 7.0%) increased significantly from 42% at baseline to 57% at follow-up, (p=0.04).
A1c improved significantly, from a mean (+/-standard deviation, SD) of 7.5% (+/-1.5) at baseline, to 7.0% (+/-1.3) at follow-up, (p<0.01).
None of the other laboratory values showed significant differences.
The proportion of patients with optimal values for low-density lipoprotein cholesterol (LDL-C) and low-to highdensity lipoprotein cholesterol (LDL-C/HDL-C) ratio increased slightly, whereas those for total cholesterol and HDL-C decreased slightly.
With the exception of HDL-C, other mean lipid values improved. None of the improvements were statistically significant (the power of the study was insufficient to accept the null hypothesis of no difference).
After the PCS intervention, the SF-12 Physical domain improved by 3.2% (from a mean value of 44.2 to 45.6) and the Mental domain improved by 3.7% (from 48.9 to 50.7). Neither change was statistically significant (the power of the study was insufficient to accept the null hypothesis of no difference).
There were significant improvements in the patients' satisfaction with pharmacy services for all domains, (p<0.01). There was a 28.4% improvement in the Technical domain (from 64.4 to 82.7), a 22.5% improvement in Consideration (from 64.1 to 78.5), a 16.5% improvement in Explanation (from 71.1 to 82.8), and a 15.0% improvement in the
